Benchtobed
Research areas
Oncology
Cardiovascular
Neurology and dementia
diabetes
obesity
GLP-1s
Immunology and autoimmune
Infectious disease and vaccines
Rare disease
Mental health research
Ageing and longevity
Womens health research
Clinical trials
Phase 1, 2, 3 and 4 explained
randomisation
blinding
control arms
primary
secondary
surrogate
Reading a trial readout
Trial failures and what they mean
Finding and joining a trial
Diversity in trial enrolment
Placebo, standard of care and ethics of control arms
Adaptive and platform trials
Basket and umbrella designs
Trial registration and ClinicalTrials.gov
Data monitoring committees and early stopping
Expanded access and right to try
Decentralised and remote trials
Regulation
FDA approval pathways
Accelerated approval and confirmatory trials
Advisory committees
Breakthrough and fast track designations
EMA and international divergence
Post-market surveillance
Generic and biosimilar approval
PDUFA dates and what they mean
Complete response letters
Orphan drug and rare paediatric designations
Boxed warnings and label changes
Recalls and safety communications
Drug shortages and manufacturing inspections
Compounded copies of approved drugs
Evidence
How to read a study
Absolute vs relative risk
Statistical significance and p-values
Effect size and confidence intervals
Preprints vs peer review
Meta-analysis and systematic review
Replication and retractions
Conflicts of interest and funding
The system
NIH funding
Academic labs and translation
Biotech and venture funding
Drug pricing and development cost
Publishing and open access
Research integrity
Patents and exclusivity
Medicare drug price negotiation
Coverage decisions and CMS national coverage analysis
Health technology assessment and cost effectiveness
Grant terminations and funding disruption
Clinical trial diversity requirements
Data sharing and individual participant data
News
Drugs & therapies
semaglutide
tirzepatide
retatrutide in trials
lecanemab
donanemab
anti-amyloid class
pembrolizumab
nivolumab
antibody drug conjugates
CAR-T
exagamglogene autotemcel
lovotibeglogene
onasemnogene
mRNA platforms
RSV vaccines
next generation COVID vaccines
inclisiran
bempedoic acid
SGLT2 inhibitors
Biosimilars and generics entering the market
Drugs withdrawn or restricted after approval
Who does the research
NIH and its institutes
NCI
NIAID
NHLBI
BARDA
ARPA-H
FDA
CBER
CDER
EMA
MHRA
Broad Institute
Dana-Farber
MD Anderson
Mayo Clinic
Memorial Sloan Kettering
Johns Hopkins
Pfizer
Merck
Eli Lilly
Novo Nordisk
AstraZeneca
Vertex
Regeneron
Moderna
Wellcome
Gates Foundation
CZI
patient foundations
Contract research organisations and trial sites
Areas
Every areas we cover.
Oncology
Alzheimers
Obesity Glp1
Cardiovascular
Multiple Sclerosis
Sickle Cell
Long Covid
Gene Therapy
No articles filed here yet. New reporting appears as it is published.